Morepen Laboratories share price
You have to be logged in to add this to Watchlist.- ₹60.17(-3.31%)June 19, 2025 15:50:44 PM IST
- NSE
- BSE
- Vol : 5.40M (NSE + BSE)Last 20 day avg : 5.14 M
Morepen Laboratories is trading -3.31% lower at Rs 60.17 as compared to its last closing price. Morepen Laboratories has been trading in the price range of 63.04 & 59.75. Morepen Laboratories has given -23.03% in this year & -8.86% in the last 5 days. Morepen Laboratories has TTM P/E ratio 21.75 as compared to the sector P/E of 22.66.The company posted a net profit of 20.32 Crores in its last quarter.Listed peers of Morepen Laboratories include Gufic Biosciences (-1.83%), Orchid Pharma (-0.84%), Morepen Laboratories (-3.31%).The Mutual Fund holding in Morepen Laboratories was at 0.05% in 30 Sep 2023. The MF holding has - from the last quarter. The FII holding in Morepen Laboratories was at 1.94% in 31 Mar 2025. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Jun 20, 2025, 01:09 AM UTC
- Dividend YieldLower than industry0.33Annual dividends as a percentage of the stock price.
- P/BLower than historical values2.85The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values27.35Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility0.70Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.09The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in March quarter by 10.11% from Rs 465.85 crore to Rs 423.07 crore, year-on-year
The company's profit declined by 28.16% year-on-year during the March quarter, dropping from Rs 28.28 crore to Rs 20.32 crore- The debt to equity of the company is higher than the industry median
- Company can comfortably pay off its interest obligations with its earnings
- R1
- 70.23
- R2
- 75.64
- R3
- 80.88
- S1
- 59.58
- S2
- 54.34
- S3
- 48.93
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Gufic Biosciences | Bearish | 355.95 | -1.83 | 3,575.79 | 52.25 | 6.06 | 0.03 | 24.97 |
| Orchid Pharma | Bearish | 685.05 | -0.84 | 3,463.73 | 35.18 | 2.77 | - | 10.39 |
| Morepen Laboratories | Moderately Bearish | 60.17 | -3.31 | 3,293.34 | 28.32 | 2.95 | - | 3.39 |
| Alembic | Neutral | 110.00 | -3.76 | 2,824.60 | 9.47 | 1.26 | 2.10 | 0.46 |
| Gujarat Themis Biosyn | Neutral | 314.00 | -3.41 | 3,421.51 | 72.68 | 14.28 | - | 11.93 |
- Promoter(s) holding is moderate at 35.65%
- FIIs are invested in this company
- FIIs holding has decreased by 0.28 percentage points from previous quarter
- Mutual Funds are not invested in this company.
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-12 | Audited Results & Final Dividend |
| 2025-02-06 | Quarterly Results |
| 2024-11-11 | Quarterly Results |
| 2024-08-12 | Quarterly Results |
| 2024-05-21 | Audited Results |
- IndustryBiotechnology & Drugs
- ISININE083A01026
- BSE Code500288
- NSE CodeMOREPENLAB
Morepen Laboratories is trading at 60.17 as on Thu Jun 19 2025 10:20:44. This is -3.31% lower as compared to its previous closing price of 62.23.
The market capitalization of Morepen Laboratories is 3293.34 Cr as on Thu Jun 19 2025 10:20:44.
The 52 wk high for Morepen Laboratories is 100.80 whereas the 52 wk low is 41.66
Morepen Laboratories can be analyzed on the following key metrics -
- TTM P/E: 21.75
- Sector P/E: 22.66
- Dividend Yield: 0.33%
- D/E ratio: 0.09
Morepen Laboratories reported a net profit of 118.02 Cr in 2025.
The Mutual Fund Shareholding was 0.05% at the end of 30 Sep 2023.